Syncom Formulations has accepted the resignation of its founder, Kedarmal Shankarlal Bankda, from the offices of Whole-Time Director and Director, effective August 11, 2026. This leadership change marks the end of more than five decades of association for Bankda, who established the company and guided its growth into a WHO-GMP and ISO 9001:2015 certified entity. The resignation is voluntary and driven by health considerations and a strategic focus on succession planning, ensuring a smooth transition to the next generation of leadership without any disagreement with the Board or management.

The company received Bankda’s resignation letter on August 8, 2026, at 10:35 AM. In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Syncom Formulations filed the requisite disclosures with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). Vaishali Agrawal, Company Secretary and Compliance Officer, signed the disclosure documents.

Resignation Details

The resignation covers both the executive role of Whole-Time Director and the non-executive position of Director. Bankda’s DIN is 00023050. The cessation of his roles takes effect at the close of business hours on August 11, 2026.

In his resignation letter, Bankda described his tenure as an "enriching journey" that began with the vision of establishing the company. He emphasized that every enduring institution must embrace timely succession planning. He stated that while giving due importance to his health and well-being, he considers it appropriate to pass on executive responsibilities to new leadership capable of carrying forward the company's values and legacy.

Board Acknowledgement

The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s exceptional leadership and unwavering commitment. The Board noted that his vision and guidance played a significant role in the company's growth and development over the past five decades. The Board expressed sincere gratitude for his dedicated service and conveyed best wishes for his good health and future endeavors.

Bankda confirmed that his decision was entirely voluntary and did not arise from any material reason or conflict with stakeholders. He expressed confidence in the company's future under its capable leadership, affirming that Syncom Formulations will continue to achieve new milestones and create lasting value.

Syncom Formulations (India) Limited has submitted the press clipping related to the extract of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's board of directors had previously approved the financial statements during a meeting held on May 22, 2026. The statutory auditors issued an unmodified opinion on the results, confirming compliance with Indian Accounting Standards (Ind AS) and SEBI regulations. The advertisement regarding the results was published in the Business Standard journal on May 23, 2026.

Q4 Performance

Syncom Formulations' Q4 consolidated net profit rose to ₹25.17 crore from ₹17.69 crore in the corresponding quarter of the previous year, reflecting a year-on-year improvement in profitability. However, Q4 revenue came in at ₹135.41 crore, compared to ₹148.88 crore in the same period last year, indicating a decline on the top line for the quarter. The quarterly results highlight a divergence between profit growth and revenue performance during the period.

Consolidated Financial Performance

For the full financial year, the company reported a consolidated net profit of ₹764.38 crore, marking a 55.5% increase from the ₹494.35 crore recorded in the previous year. Total income for the period grew to ₹5,205.11 crore from ₹4,824.47 crore in FY25. Revenue from operations stood at ₹4,891.71 crore, while other income contributed ₹313.40 crore.

Standalone Results

On a standalone basis, the net profit for the year ended March 31, 2026, reached ₹760.08 crore, up from ₹488.72 crore in the corresponding period of the previous year. Total standalone income increased to ₹5,175.39 crore from ₹4,800.41 crore. Revenue from operations was reported at ₹4,865.73 crore. The company noted that it had restated its Earnings Per Share (EPS) calculations for prior periods to comply with Ind AS 33, using Profit After Tax instead of Total Comprehensive Income.

Segment Performance

The company operates across three primary segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The Pharmaceuticals segment remained the primary revenue driver, contributing ₹5,157.34 crore to the total segment revenue for the year. The company also recognized an incremental cost of ₹87.81 lakh during the year related to the new Labour Codes notified by the Government of India.

Financial Position and Cash Flows

As of March 31, 2026, the company's consolidated total assets stood at ₹5,338.45 crore, compared to ₹4,132.81 crore in the previous year. Equity share capital remained constant at ₹940 crore. The net cash generated from operating activities for the year was ₹580.79 crore, while cash and cash equivalents at the end of the period totaled ₹51.48 crore. The following table summarizes the key full-year financial metrics: